$ACXP News

Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update

Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect

Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target

Acurx Pharmaceuticals Says First Patient Enrolled In New PATHFINDER Clinical Trial In Patients With Multiply Recurrent C. Difficile Infection

Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call

Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures

Acurx Pharmaceuticals Files Prospectus For 1.5M Offering

Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

FDA Conditionally Accepts Acurx Pharmaceuticals' Brand Name CIFBEZY for Ibezapolstat

Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update

Acurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Acurx Pharmaceuticals Announces Intent For Further Discussion With FDA Regarding Ibezapolstat's Phase 3 Clinical Program, Scope Of Its Planned NDA